X4PharmaceuticalsInc_NASDAQ_XFOR_202310-K.pdf

《X4PharmaceuticalsInc_NASDAQ_XFOR_202310-K.pdf》由会员分享，可在线阅读，更多相关《X4PharmaceuticalsInc_NASDAQ_XFOR_202310-K.pdf（148页珍藏版）》请在三个皮匠报告上搜索。

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-K(Mark One)xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31,2023oroANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934Fo

2、r the transition period from toCommission File Number:001-38295_X4 PHARMACEUTICALS,INC.(Exact name of registrant as specified in its charter)_Delaware(State or other jurisdiction of incorporation or organization)27-3181608(I.R.S.Employer Identification No.)61 North Beacon Street,4th FloorBoston,Mass

3、achusetts(Address of principal executive offices)02134(Zip Code)(857)529-8300(Registrants telephone number,including area code)_Securities registered pursuant to Section 12(b)of the Act:Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon StockXFORThe Nasdaq Stock Mark

4、et LLCSecurities registered pursuant to Section 12(g)of the Act:noneIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section

5、15(d)of the Act.Yes No Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or forsuch shorter period that the registrant was required to file such reports),and(2)has bee

6、n subject to such filing requirements for the past 90 days Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(of this chapter)duringthe preceding 12 months(of for such shorter p